Image for post
Image for post

Understanding heart diseases, particularly the risk of heart attack, strokes, valvular diseases requiring stents or cardiac surgery, is a dynamic field. Heart diseases, particularly coronary heart disease (CHD), remain the #1 risk of disability and death in western countries in both men and women. The traditional risk factors for early CHD are smoking, diabetes mellitus, hypertension, elevated cholesterol, and a family history of early CHD. The standard lipid profile has served as a mainstay of CHD risk assessment for decades.

Lipoprotein(a) (Lp[a]) is a type of cholesterol particle that is not measured on standard lab panels. Measure Lp(a) can help refine strategies of CHD risk assessment. Lp(a) has huge importance as it is estimated to be elevated in approximately 20% of the world’s population and is genetically determined. It is a complex structure that has a low-density lipoprotein (LDL) particle with an added apolipoprotein(a) via a totally different hepatic pathway than LDL cholesterol. If inherited, the level of Lp(a) in the blood is elevated and has the potential to do harm by 1–2 years of age! Ongoing strategies to lower Lp(a) in patients at risk or with proven CHD are a recent focus of pharmaceutical companies but none are approved for use at this time. This case study indicates that “natural” approaches using diet and supplements may have a profound impact on the level of Lp(a). …


Joel Kahn

Professor of Cardiology, Summa cum Laude grad, Kahn Center for Longevity and GreenSpace Cafe. @drjkahn. Author The Plant Based Solution NEW

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store